Investigational drug · Phase 3
Qishen Yiqi Dripping Pills 2 bags
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "Qishen Yiqi Dripping Pills 2 bags"
First trial start
2021
Oct 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Qishen Yiqi Dripping Pills 2 bags", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
- Chronic Heart Failure With Preserved Ejection Fraction
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Qishen Yiqi Dripping Pills 2 bags" as an intervention, largest first.
- Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUrePivotal-lookingRecruiting
Tasly Pharmaceutical Group Co., LtdIndustry
NCT07687186 · 636 participants (planned) · Start Aug 21, 2026 · Primary completion Jun 22, 2028
Drug: Qishen Yiqi Dripping Pills 2 bags; Qishen Yiqi Dripping Pills placebo 2 bags · For: Heart Failure
Sites: Bozhou, China; Hefei, China; Suzhou, China · 60 sites in all
- Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart FailurePivotal-lookingCompleted
Tasly Pharmaceutical Group Co., LtdIndustry
NCT04983043 · 228 participants · Start Jul 13, 2021 · Primary completion Nov 27, 2024
Drug: Low dose QiShen YiQi Dripping Pills 3 bags; High dose QiShen YiQi Dripping Pills 3 bags and 1 more · For: Chronic Heart Failure With Reduced Ejection Fraction
Sites: Hefei, China; Huainan, China; Suzhou, China · 23 sites in all
- Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)Pivotal-lookingCompleted
Tasly Pharmaceutical Group Co., LtdIndustry
NCT06006689 · 228 participants · Start Sep 15, 2023 · Primary completion Apr 16, 2025
Drug: Qishen Yiqi Dripping Pills placebo 3 bags; Low dose Qishen Yiqi Dripping Pills 3 bags and 1 more · For: Diabetic Kidney Disease
Sites: Beijing, China; Guangzhou, China; Shijiazhuang, China · 16 sites in all
- Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection FractionPivotal-lookingCompleted
Tasly Pharmaceutical Group Co., LtdIndustry
NCT04944706 · 225 participants · Start Oct 18, 2021 · Primary completion Jan 22, 2025
Drug: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time; Qishen Yiqi dripping pills 4 bags/time and 1 more · For: Chronic Heart Failure With Preserved Ejection Fraction
Sites: Bengbu, China; Beijing, China; Chongqing, China · 16 sites in all
Tasly Pharmaceutical Group Co., LtdIndustry
NCT04471298 · 36 participants · Start Sep 21, 2020 · Primary completion Jan 11, 2021
Drug: Qishenyiqi dripping pills, 6 bags; Qishenyiqi dripping pills, 9 bags and 4 more · For: Healthy Participants
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- AZD3427Phase 21 trial
AstraZeneca · Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.